In contrast, men did not face the same increased risk of cerebrovascular disease later in life, reported authors of a new study.

Your daily dose of the clinical news you may have missed.

The FDA has assigned a PDUFA action date of January 25, 2025 for the monthly IV maintenance dose.

The investigational combination vaccine elicited higher immune responses vs licensed comparator vaccines in 2 independent age groups, the company said.

Abbott becomes the second company to receive FDA clearance for an over-the-counter continuous glucose monitoring system.

Your daily dose of the clinical news you may have missed.

GSK announced today approval by the US FDA of a label expansion for the adjuvanted RSV vaccine that adds adults aged 50 to 59 years who are at elevated risk for RSV disease to the vaccine’s current indication.

Your daily dose of the clinical news you may have missed.

There are lots of products in development for weight loss and to treat other metabolic diseases which means more options for more people.

Your daily dose of the clinical news you may have missed.

ENDO 2024. New findings suggest GLP-1RAs and SGLT-2is may be more beneficial than other diabetes agents for patients with T2D and MASLD.

Despite its limitations for use in other populations, a high BMI proved a very good predictor of dangerous fat mass index in youth aged 8 to 19 years in this study.

Your daily dose of the clinical news you may have missed.

ENDO 2024. The expert panel suggests children, pregnant persons, adults aged ≥75 years, and adults with prediabetes consume more vitamin D than the recommended daily allowance.

Your daily dose of the clinical news you may have missed.

The over-the-counter antigen test, for use at home or at point of care, discriminates between SARS-CoV-2 and influenza A and B in 15 minutes.

mRESVIA is Moderna's second mRNA-based vaccine and will be shipped in prefilled syringes, a desirable feature that could save clinical time, prevent errors.

The interactive tool provides clinicians and patients a real-time look at GLP-1RA availability.

The dual interleukin-4, 13 inhibitor reduced COPD exacerbation rates by as much as 34% for individuals with COPD with type 2 inflammation, Bhatt explains.

FDA has no concerns about the "approvability" of dupilumab for the new indication but needs additional time to review phase 3 data it requested early in May.